Karandinos George, Unick Jay, Ciccarone Daniel
Division of General Internal Medicine, Massachusetts General Hospital, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.
Addiction. 2025 May;120(5):1040-1045. doi: 10.1111/add.16740. Epub 2025 Jan 22.
Opioid smoking is becoming more common in the United States. The aim of this analysis was to estimate relative mortality risk among those who primarily smoke opioids compared with those who inject.
Retrospective propensity score-matched cohort analysis.
2006-2021 US treatment episode data from SAMHSA TEDS-D.
We matched 287 481 individuals in a substance use treatment program reporting smoking opioids as their primary substance use to an equal weighted number of individuals in a substance use treatment program reporting injecting opioids as their primary substance use. The majority of individuals reporting smoking were male (62.6%), 21-29 years old (47.9%), white (65.7%), independently housed (54.3%) and in the West Census Region (70.3%). Cohort characteristics were closely balanced after matching.
The outcome of interest was death during a treatment episode. Variables used for matching were year, opioid category, gender, race/ethnicity, age category, census region, housing status, employment status, number of prior treatment admissions, variables associated with opioid use severity (opioid use frequency, treatment setting intensity, age at first opioid use, use of medication-assisted treatment) and other reported substance use (methamphetamine, alcohol, benzodiazepines, cocaine).
The mortality rate was 6.5 [95% confidence interval (CI) = 5.9-7.1] per 1000 person-years in the smoking cohort and 9.7 (95% CI = 8.8-10.8) per 1000 person-years in the injection cohort, with a mortality rate ratio of 0.67 (95% CI = 0.58-0.77).
Among individuals in substance use treatment in the United States, those who usually smoke opioids appear to have a lower all-cause mortality risk than those who usually inject.
在美国,吸食阿片类药物正变得越来越普遍。本分析的目的是估计主要吸食阿片类药物者与注射阿片类药物者相比的相对死亡风险。
回顾性倾向评分匹配队列分析。
2006年至2021年美国药物滥用和精神健康服务管理局(SAMHSA)治疗事件数据集(TEDS-D)中的数据。
我们将物质使用治疗项目中报告主要使用阿片类药物吸烟的287481人,与物质使用治疗项目中报告主要使用阿片类药物注射的同等加权人数的个体进行匹配。报告吸烟的个体大多数为男性(62.6%),年龄在21至29岁之间(47.9%),白人(65.7%),独立居住(54.3%),且位于西部人口普查区(70.3%)。匹配后队列特征紧密平衡。
感兴趣的结局是治疗期间的死亡。用于匹配的变量包括年份、阿片类药物类别、性别、种族/族裔、年龄类别、人口普查区、住房状况、就业状况、既往治疗入院次数、与阿片类药物使用严重程度相关的变量(阿片类药物使用频率、治疗机构强度、首次使用阿片类药物的年龄、药物辅助治疗的使用情况)以及其他报告的物质使用情况(甲基苯丙胺、酒精、苯二氮卓类药物、可卡因)。
吸烟队列的死亡率为每1000人年6.5[95%置信区间(CI)=5.9 - 7.1],注射队列的死亡率为每1000人年9.7(95%CI = 8.8 - 10.8),死亡率比为0.67(95%CI = 0.58 - 0.77)。
在美国接受物质使用治疗的个体中,通常吸食阿片类药物者的全因死亡风险似乎低于通常注射阿片类药物者。